What is the daily dosage of capmatinib/touradida?

Capmatinib (Capmatinib) is a targeted drug mainly used to treat non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations. This drug reduces the growth and spread of cancer cells by inhibiting the function ofMET receptor tyrosine kinase. For eligible patients, correct dosing is critical to ensure optimal treatment results.

The recommended dose of capmatinib is400 mg twice daily. Patients can choose to take the medication with or without food, with or without food. However, it is recommended that patients try to take it twice a day and regularly to ensure that the drug reaches a constant concentration in the body and increase the therapeutic effect.

1. Dose schedule: The dosage schedule of capmatinib is twice a day, 400mg each time. Patients should strictly follow the doctor's advice, take medication on time and avoid missing doses. If you miss a dose, you should take it as early as possible on the same day and resume your normal medication schedule the next day.

2. How to take the drug: Capmatinib tablets should be swallowed whole and avoid chewing or crushing the tablets to ensure stable absorption of the drug.

3. Treatment cycle: During treatment, patients should undergo regular blood tests and liver function monitoring to evaluate the effects and potential side effects of the drug. Treatment with capmatinib is usually continued until disease progression or unacceptable side effects occur.

In short, the dosage of capmatinib needs to be adjusted according to the patient's individual situation and the doctor's advice. The patient must pay close attention to the effects and side effects of the drug during treatment, and implement each medication plan in accordance with the doctor's instructions.

Keyword tags: capmatinib,Capmatinib, MET gene mutation, non-small cell lung cancer, targeted therapy, drug dosage, medication method, treatment plan, side effects

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/tabrecta